Uterine corpus apoplectic leiomyoma

Summary

Uterine corpus apoplectic leiomyoma (MONDO:0004161) is a disease. A subtype of uterine corpus leiomyoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	uterine corpus apoplectic leiomyoma
Mondo ID	MONDO:0004161
DOID	DOID:7241
NCIT	C40165
UMLS	C1519852
MedGen	274364
GARD	0023855
Is cancer (heuristic)	no

Also known as: uterine corpus hemorrhagic cellular leiomyoma · uterine corpus leiomyoma with apoplectic change

Disease family

This is a subtype of uterine corpus leiomyoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign muscle neoplasm › benign smooth muscle neoplasm › leiomyoma › uterine corpus leiomyoma › uterine corpus apoplectic leiomyoma

Related subtypes (10): submucous uterine fibroid, subserous uterine fibroid, uterine corpus epithelioid leiomyoma, uterine corpus dissecting leiomyoma, uterus interstitial leiomyoma, uterine corpus myxoid leiomyoma, uterine corpus lipoleiomyoma, uterine corpus bizarre leiomyoma, uterine corpus diffuse leiomyomatosis, uterine corpus cellular leiomyoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.